May 23 (Reuters) - Prometic Life Sciences Inc PLI.TO :
* Says presents new data on PBI-4050 and plasminogen
* Prometic Life Sciences - PBI-4050 monotherapy and combination with nintedanib demonstrated promising results in treatment of idiopathic pulmonary fibrosis
* Says plasminogen administration shown to reduce acute lung injury (ALI) in an acute pancreatitis model Source text for Eikon: ID:nCNWCYnxNa Further company coverage: PLI.TO